D. Stambuk

The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.

M. Morgan, V. Marks, N. R. Scott, 1989, British journal of clinical pharmacology.

Amino acid tolerance in cirrhotic patients following oral protein and amino acid loads

M. Morgan, K. Hawley, M. Morgan, 1990, Alimentary pharmacology & therapeutics.

Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.

M. Morgan, K. Hawley, D. Stambuk, 1987, Journal of hepatology.

Zidovudine treatment of patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex: St Stephen's Hospital experience.

D. Hawkins, B. Gazzard, D. Stambuk, 1989, The Journal of infection.

Pharmacokinetics of famotidine in normal subjects and in patients with chronic liver disease

M. Morgan, S. Mann, J. Cottrell, 1990, Alimentary pharmacology & therapeutics.

The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.

D. Hawkins, C. Farthing, M. Youle, 1989, The Quarterly journal of medicine.

The measurement of 1,2-propanediol, D, L-2,3-butanediol and meso-2,3-butanediol in controls and alcoholic cirrhotics.

J. Casazza, M. Morgan, R. Veech, 1987, Alcohol and alcoholism (Oxford, Oxfordshire). Supplement.

Caffeine clearance and biotransformation in patients with chronic liver disease.

M. Morgan, V. Marks, J. Chakraborty, 1988, Clinical science.

Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.

M. Morgan, D. Stambuk, 1986, Postgraduate medical journal.